NCT00121030已完成2 期
An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Patients With Gynecological Malignancies Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Amgen
- 主要终点
- Anemia correction
研究概览
简要总结
The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in gynecological cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subjects receiving multi-cycle chemotherapy for gynecological cancer - Anemia due to chemotherapy (hgb less than or equal to 11.0 g/dL) - Expected to receive greater than or equal to 8 additional weeks of chemotherapy as part of their planned treatment - Karnofsky Performance Scale (KPS) greater than or equal to 50% - Adequate renal function - Adequate liver function
排除标准
- •Iron deficiency - Known positive test for human immunodeficiency virus (HIV) infection
结局指标
主要结局
Anemia correction
次要结局
- Patient preference
- Activities of daily living
研究者
相似试验
已完成
2 期
Treatment for Patients Suffering From Anemia Due to ChemotherapyBreast CancerAnemiaNCT00120692Amgen
已完成
2 期
Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to ChemotherapyAnemiaNon-Small Cell Lung CancerNCT00120679Amgen
撤回
2 期
Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma PatientsMalignant GliomaNCT01952886Duke University
已完成
2 期
Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)Myelodysplastic SyndromeNCT00050154Johnson & Johnson Pharmaceutical Research & Development, L.L.C.82
终止
1 期
A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDSAnemia in Myelodysplastic SyndromesNCT04623996Sumitomo Pharma America, Inc.2